Hikma Pharmaceuticals Plc Notice of Results (8920B)
February 04 2020 - 4:07AM
UK Regulatory
TIDMHIK
RNS Number : 8920B
Hikma Pharmaceuticals Plc
04 February 2020
London, February 4, 2020 - Hikma Pharmaceuticals PLC (Hikma,
Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated
Ba1/stable Moody's and BB+/positive S&P), will announce its
preliminary financial results for the year ended 31 December 2019
on Thursday 27 February 2020.
A presentation and webcast for analysts will be held on 27
February 2020 at 9:30am GMT, for further information about the
meeting, please get in contact with Tiina Lugmayer -
Tiina@Hikma.uk.com.
To join via conference call please dial:
United Kingdom 0800 640 6441
United Kingdom (local) 020 3936 2999
All other locations +44 20 3936 2999
Access code: 442936
The results presentation and a webcast recording of the event
will be available on the Company's website at www.hikma.com or
https://webcast.openbriefing.com/hikma-prelim2019/.
Playback facility:
A playback of the conference call will be available up to six
months after the presentation.
UK: 020 3936 3001
USA: 1 845 709 8569
All other locations: +44 20 3936 3001
Access code: 169303
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 7776
Affairs 477050
FTI Consulting
Ben Atwell +44 (0)20 3727 1000
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,400 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORGZGGZLDKGGZG
(END) Dow Jones Newswires
February 04, 2020 04:07 ET (09:07 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024